Search company, investor...
Seahorse Bioscience company logo

Seahorse Bioscience

seahorsebio.com

Founded Year

2000

Stage

Acquired | Acquired

Total Raised

$28.84M

Valuation

$0000 

About Seahorse Bioscience

Seahorse Bioscience provides instruments and consumable labware products for biological research and drug discovery. Seahorse Bioscience's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers. Seahorse Bioscience XF Analyzers and stress test kits are the industry standard in cellular bioenergetic measurements. Scientists worldwide are advancing research in understanding the role of cell metabolism in Neurodegeneration, Aging, Cancer, Cardiovascular, Cell Physiology, Toxicology & Hepatobiology, Immunology, Infectious Diseases, Mitochondrial Diseases, Model Organisms, Obesity, Diabetes, Metabolic Disorders, Screening, and Translational Medicine.

Headquarters Location

16 Esquire Road

North Billerica, Massachusetts, 01862,

United States

978-671-1600

Missing: Seahorse Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Seahorse Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Seahorse Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Seahorse Bioscience is included in 5 Expert Collections, including Medical Devices.

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Diabetes

1,903 items

H

Health IT

7,901 items

Seahorse Bioscience Patents

Seahorse Bioscience has filed 17 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/19/2015

7/23/2019

Biotechnology, Luminescence, Spectroscopy, Tectonic plates, Molecular biology

Grant

Application Date

8/19/2015

Grant Date

7/23/2019

Title

Related Topics

Biotechnology, Luminescence, Spectroscopy, Tectonic plates, Molecular biology

Status

Grant

Latest Seahorse Bioscience News

Multifunctional Graphene Oxide Nanodelivery Platform for Breast Cancer Treatment

Dec 15, 2022

Yousheng Mo,1,&ast; Wei Liu,2,&ast; Piaoxue Liu,2 Qiao Liu,3 Zhongyu Yuan,4 Qi Wang,2 Dongsheng Yuan,2 Xiao-Jia Chen,3 Tongkai Chen2 1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, People’s Republic of China; 2Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People’s Republic of China; 3State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, People’s Republic of China; 4Department of Medical Oncology, Sun Yat-Sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China &ast;These authors contributed equally to this work Background: Breast cancer (BC) has the highest global prevalence among all malignancies in women and the second highest prevalence in the overall population. Paclitaxel (PTX), a tricyclic diterpenoid, is effective against BC. However, its poor solubility in water and the allergenicity of its dissolution medium limited its clinical application. Methods: In this work, we established a multifunctional graphene oxide (GO) tumor-targeting drug delivery system using nanosized graphene oxide (nGO) modified with D-tocopherol polyethylene glycol succinate (TPGS) and arginine-glycine-aspartic acid (RGD) for PTX loading. Results: The obtained RGD-TPGS-nGO-PTX was 310.20± 19.86 nm in size; the polydispersity index (PDI) and zeta potential were 0.21± 0.020 and − 23.42 mV, respectively. The mean drug loading capacity of RGD-TPGS-nGO-PTX was 48.78%. RGD-TPGS-nGO-PTX showed satisfactory biocompatibility and biosafety and had no significant toxic effects on zebrafish embryos. Importantly, it exerted excellent cytotoxicity against MDA-MB-231 cells, reversed multi-drug resistance (MDR) in MCF-7/ADR cells, and showed significant anti-tumor efficacy in tumor-bearing nude mice. Conclusion: These findings strongly suggested that the multifunctional GO tumor-targeting drug delivery system RGD-TPGS-nGO-PTX could be used in clinical settings to improve PTX delivery, reverse MDR and increase the therapeutic efficacy of BC treatment. Keywords: breast cancer, paclitaxel, targeted delivery, multidrug resistance Introduction Breast cancer (BC) has the highest global prevalence among all malignancies in women and the second highest prevalence in the overall population. 1 The most common therapeutic strategies for BC conservative surgery, radiation therapy, and chemotherapy cause several adverse effects, including lymphedema, damage to normal tissue, and tumor recurrence. 2–4 Pharmacological strategies are indispensable to accessible and effective treatments for BC patients. 5 , 6 Nevertheless, the drugs currently used to treat BC have unsatisfactory efficacy due to poor tumor targeting and drug resistance. 7 , 8 Therefore, new strategies must be explored for improving drug efficacy and targeting, overcoming drug resistance, and reducing off-target toxicity. Nanomedicine has entered the field of view of researchers for its excellent targeted therapeutic properties. The known nanocarriers for targeted therapy of breast cancer include albumin-coated copper nanoparticles (ACuNPs), 9 chitosan/carbon quantum dot/aptamer complex (CS-CQD-apt), 10 agarose-polyethylene pyridoxanidone-hydroxyapatite (AG-PVP-Hap) 11 and many other nanocarriers. In addition, a variety of novel nanomaterials with excellent performance have been developed to significantly enhance the bioavailability, biocompatibility, and tumor targeting of natural compounds such as curcumin 12 and sesamol. 13 , 14 Graphene oxide (GO), an oxidized form of graphene, has recently been developed as a novel two-dimensional carbon nanomaterial. 15 It has received extensive attention in drug delivery studies due to their good biocompatibility and low toxicity. 16 , 17 The surface of GO has hydrophilic groups, including hydroxyl (–OH), carboxyl (–COOH) and methoxyl (CH3O-) groups, which can be modified and biofunctionalized. 18 Furthermore, nanosized GO (nGO) possesses good dispersity in water and also has a smaller particle size and good stability. 19 Importantly, nGO has a high drug loading capacity and excellent photothermal conversion performance and is easy to prepare. 20 One major challenge in the efficient treatment of cancer is MDR. 21 In BC, MDR is often caused by an increase in P-glycoprotein (P-gp) expression on the surface of tumor cells. 22 As an ATP-powered efflux pump, P-gp removes anti-tumor drugs from cancer cells, rendering them ineffective. 23 D-tocopherol polyethylene glycol succinate (TPGS), which has received approval from the US Food and Drug Administration, is a multifunctional drug excipient with good biocompatibility. 24 TPGS has been reported to reverse MDR by inhibiting P-gp transport system, 25 and is also robust in prolonging the retention time of anti-tumor drug in cancer cells and enhancing the drug accumulation. 26 Integrin αvβ3 is an important member of the integrin family. This protein has a series of functions in tumors, and is involved in angiogenesis, cell proliferation, invasion, and metastasis in different cancer types. 27 , 28 Integrin αvβ3 is closely associated with angiogenesis in BC. 29 Reports showed that arginine-glycine-aspartic acid (RGD) sequences specifically bind to integrin αvβ3. 30 , 31 Moreover, recent studies have confirmed that RGD can act as an excellent tumor-targeting ligand and that RGD-conjugated nano-carriers can target tumors effectively. 32 Paclitaxel (PTX), a tricyclic diterpenoid present in bark and needles from the plant Taxus brevifolia, is used to treat several malignancies, including BC and ovarian, head and neck, and lung cancers. 33–36 However, PTX has many disadvantages, such as poor water solubility, poor tumor targeting, lack of efficacy in cases of multi-drug resistance (MDR), and low bioavailability, which limits its clinical application. 37–41 Recently, the research on the use of nanomaterials to solve these problems has gained wide attention. 42–44 Given the specific properties of BC, such as MDR and the role of integrin αvβ3, as well as the drawbacks of PTX, we attempted to develop a system that allows targeted PTX delivery, reversal of MDR, and enhanced treatment efficacy against BC. Therefore, we established a multifunctional nGO tumor-targeting drug delivery system (RGD-TPGS-nGO-PTX). We first synthesized and characterized this system and then evaluated its anti-tumor effects in vitro as well as in vivo ( Scheme 1 ). Scheme 1 Schematic of the in vitro and in vivo studies on the anti-tumor effects of RGD-TPGS-nGO-PTX. Materials and Methods Materials PTX and GO were purchased from Nantong Feiyu Biological Technology Co., Ltd (Nantong, China) and Qingdao Baichuan Graphite Co., Ltd (Qingdao, China). TPGS was obtained from Shanghai YuanYe Biotechnology Co., Ltd (Shanghai, China). RGD was obtained from Qiangyao Biotechnology Co. Ltd. (Shanghai, China). Dulbecco’s Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), and penicillin-streptomycin were purchased from GIBCO, Invitrogen Corporation (USA). MTT solution was purchased from Sigma Aldrich (USA). The live/dead viability assay kit was obtained from Nanjing KeyGen Biotech. Inc. (Nanjing, China). MDA-MB-231 human breast cancer cells and MCF-7/ADR cells were obtained from the Science and Technology Innovation Center of Guangzhou University of Chinese Medicine (Guangzhou, China) and Beijing Cell bank (Beijing, China), respectively. Zebrafish wild-type AB lines were purchased from China Zebrafish Resource Center (Wuhan, China). Female BALB/c-Nude mice (4–5 weeks of age) were purchased from SPF (Beijing) Biotechnology Co., Ltd. (Beijing, China). All flasks and plates used for cell culture were obtained from Corning Costar Corp. (Cambridge, MA, USA). The Milli-Q Plus System (Millipore Corporation, Bedford, MA, USA) was used to obtain ultrapure water. Synthesis of GO and nGO GO was prepared using a modified version of Hummer’s method. Briefly, 4 g of graphite powder was added to 100 mL of H2SO4 kept on ice, and the mixture was stirred continuously. Subsequently, 25 g KMnO4 was added slowly, and the mixture was incubated at a constant temperature of 35°C for 1 h. Further, 200 mL of deionized water was added to the reaction mixture, and the mixture was incubated at 98°C for 30 min. Subsequently, the mixture underwent filtration and thorough washes with deionized water until a pH of 7 was reached. The mixture was then dried under vacuum at 60°C, and GO was obtained. The GO was then suspended in deionized water and broken into small particles using an ultrasonic cell crusher, and nGO was obtained after filtration and freeze-drying ( Figure 1A ). Figure 1 Schematic of RGD-TPGS-nGO-PTX synthesis. Synthesis of TPGS-NHS (A), RGD-TPGS (B), and RGD-TPGS-nGO-PTX (C). Synthesis of TPGS-RGD: TPGS-RGD was prepared as described in the previous study. 24 In brief, TPGS, succinic anhydride (SA), and 4-dimethylaminopyridine (DMAP) were dissolved in 15 mL of dichloromethane. The mixture was stirred constantly for 24 h and then underwent filtration and dialysis. The resultant TPGS-SA was stored at 4°C. Next, TPGS-SA, N-hydroxysuccinimide (NHS), and N, N’-dicyclohexylcarbodiimide (DCC) were dissolved in 10 mL of dichloromethane; the mixture was stirred and then filtered to obtain the intermediate product TPGS-NHS. Following this, TPGS-NHS and RGD were dissolved in dimethylformamide (DMF). The mixture was stirred constantly for 24 h and triethylamine was added in a dropwise manner. The resultant TPGS-RGD was obtained after filtration and dialysis ( Figure 1B ). Synthesis of RGD-TPGS-nGO-PTX: RGD-TPGS-nGO-PTX was prepared as previously described. 17 A 1 mL nGO solution was mixed with 1 mL of a PTX solution at room temperature for 24 h under constant stirring to allow PTX to adsorb onto nGO. Next, nGO-PTX was mixed with TPGS-RGD at the ratio of 1:1 followed by dialysis and vacuum freeze drying to obtain RGD-TPGS-nGO-PTX ( Figure 1C ). RGD-TPGS-nGO-PTX Characterization nGO, RGD-TPGS-nGO, and RGD-TPGS-nGO-PTX were characterized. The morphology of these particles was observed using a transmission electron microscope (TEM) (H-600, Hitachi, Japan), and the particle size and zeta potential analysis were using Dynamic Light Scattering (DLS) (NICOMP 380 Z3000, US). We examined the intermediate products and the functional groups of particles using FT-IR (Nicolet™ iN10 MX Infrared Imaging Microscope/Nicolet 6700 FT-IR Spectrometer). Elemental analysis was performed using a Vario EL cube (Elementar). To detect the drug-loading capacity of RGD-TPGS-nGO-PTX, we created standard curves of absorbance vs concentration for PTX. External calibration was used to determine drug loading. To determine stability, RGD-TPGS-nGO, nGO, and RGD-TPGS-nGO were diluted to 0.25 mg/mL in 0.9% saline or double-distilled water. The diluted samples were placed on the stage of a tester and stability was observed on the first, third, seventh, and fifteenth days. Cell Culture and Animal Care The study received approval from the Animal Ethics Committee of Guangzhou University of Chinese Medicine and followed all national regulations for the care and use of experimental animals. We cultured MDA-MB-231 cells (human breast cancer cells) in DMEM (containing 10% FBS and 100 U/mL of penicillin and streptomycin each) under sterile conditions at 37°C and 5% CO2. In contrast, we cultured MCF-7/ADR cells (human breast carcinoma cells showing drug resistance) in RPMI 1640 medium (containing 10% heat-inactivated FBS, 100 U/mL penicillin G, and 100 μg streptomycin) at 37°C and 5% CO2. Wild-type zebrafish were grown under a 14/10 h light/dark cycle at 28.0±1°C (pH, 6.8–7.5). At maturity, male and female zebrafish were added to a fertilization tank at a 1:1 ratio. Following the light cycle, fertilized embryos were collected, and 1-phenyl-2-thiourea treatment was used to prevent pigment development. BALB/c‐nu/nu female mice (4–5 weeks old) were maintained under 12 h light/dark cycles at 23±2°C and 50±20% relative humidity. They all received standard laboratory chow and water ad libitum. In vivo Examination of Toxicity Zebrafish are widely used in drug discovery, drug development, and toxicological screening as a small vertebrate model, 45 , 46 owing to the high similarity between their morphology and physiology and that of mammals 39 , 45 Moreover, zebrafish embryos and larvae are almost transparent, which enables the easy surveillance of organ development. 47 , 48 In this study, healthy zebrafish embryos (5 hpf) were placed in 24-well dishes (20 per well) and treated with 250 μg/mL of nGO, TPGS, and RGD-TPGS-nGO. The survival rate of zebrafish embryos was evaluated based on their heartbeat, activity, and circulation at 96 hpf. The hatching rate, heart rate, and body length were also examined at this stage. Cell Viability Assay The viability of MCF-7/ADR cells was examined with MTT assays. After 24 h of culture, cells were treated with different concentrations of RGD-TPGS-nGO-PTX. The supernatant was discarded after 24 h of incubation, and 90 μL DMEM and 10 μL MTT solution was added to each well; the cells were then incubated in the dark for 4 h. Following this, 150 μL dimethyl sulfoxide (DMSO) (Guangzhou Chemical Reagent Factory, Guangzhou, China) was added to each well after discarding the supernatant, and cells were incubated for 10 min with shaking. A microplate reader (Multiskan FC, Thermo Scientific, United States) was used to measure absorbance at 490 nm and cell viability was calculated. Live/Dead Cell Staining MDA-MB-231 cells were seeded in culture medium (5 × 104 cells per well) and allowed to attach. After 24 h, the old medium was discarded and fresh medium containing RGD-TPGS-nGO, PTX, or RGD-TPGS-nGO-PTX was added. The cells were treated with different concentration of the agents (1.25, 0.625, 0.3125, 0.15625 µg/mL) for 24 h. Subsequently, the supernatant was discarded, and the cells were incubated in the staining solution (2 μM calcein-AM and 8 μM PI) for 30 min under dark conditions. Finally, the cells were imaged using a fluorescence microscope (DMi8, Leica, Germany). Mitochondrial Oxygen Consumption MCF-7/ADR cells were seeded in culture medium (3 × 103 cells per well) and allowed to attach for 24 h. After the cells were treated with different agents, OCR was examined using a Seahorse XF96 Extracellular Flux analyzer (Seahorse Bioscience, MA, USA). For another set of experiments, the MCF-7/ADR cells were cultured in medium (2.5 × 104 cells per well) for 24 h and subsequently treated with nG, TPGS-nGO, and RGD-TPGS-nGO (25, 50, and 100 μM), and 10 μM NaN3 solution was used as the positive control group. After 36 h of incubation, the old media were replaced with 175 μL of FX Assay-Modified DMEM containing 5.5 mM glucose, 1 mM pyruvate, and 2 mM glutamine (Agilent Technologies) and cells were cultured in a CO2-free incubator for 1 h. Mitochondrial and cellular metabolic profiles were then obtained using a mitochondrial stress assay. 49 Animal Groups and Treatment We injected a 200 μL suspension of MDA-MB-231 cells (1.12×107 cells/mL) into the mammary fat pad of 20 female BALB/c-Nude mice to establish an orthotopic mouse model of BC. When tumors grew to 40–60 mm3 in volume, the mice were randomized into the control, PTX, TPGS-nGO-PTX, and RGD-TPGS-nGO-PTX groups (n = 5/group). Mice in the PTX, TPGS-nGO-PTX and RGD-TPGS-nGO-PTX groups received i.p. injections of 5 mg/kg PTX, TPGS-nGO-PTX, and RGD-TPGS-nGO-PTX, once every three days for 30 days. Equal volumes of normal saline were administered to the control group via i.p. injections over the same time points. Assessment of Anti-Tumor Effect and PTX Content in Tumors After the final drug treatment, mice were weighed and euthanized. Tumor tissue samples (100 mg) were collected from each group and homogenized in 70% methanol. Homogenates underwent centrifugation at 12,000 ×g at 4°C for 10 min. Subsequently, PTX concentrations in the tumor tissues of mice from each group were detected by analyzing the collected supernatant with high-performance liquid chromatography. Statistical Analysis All the data are expressed as means ± standard deviations. All multiple-group comparisons were performed using one-way analysis of variance, and differences between two groups were analyzed using two-tailed Student’s t-tests. A P-value less than 0.05 was considered to indicate statistical significance. Results and Discussion Characterization of the Synthesized TPGS-RGD To better verify the accuracy of synthesis, we performed FTIR detection of TPGS and TPGS-RGD. According to Figure 2A and B , the functional group types of TPGS and TPGS-RGD are basically similar. In the infrared spectrum of TPGS-RGD, compared with TPGS, there are two characteristic absorption peaks at 1576.39 cm−1 and 1627.35 cm−1, which are the unique infrared absorption peaks of the amide bond. It is proved that TPGS and RGD can combine smoothly through an amide bond to produce a new compound TPGS-RGD. Figure 2 Characterization of RGD-TPGS-nGO-PTX. FT-IR analysis spectroscopy of TPGS (A) and RGD-TPGS (B), green arrows indicate which are the unique infrared peaks of the amide bond. Representative corresponding particle size parameters and TEM images (right) (C–E). (F) Stability analysis of nGO and GD-TPGS-nGO, the samples were dispersed in double-distilled water (H2O) or 0.9% normal saline (NS) at a concentration of 0.25 mg/mL. Characterization of RGD-TPGS-nGO-PTX DLS graph shows that nGO, RGD-TPGS-nGO, and RGD-TPGS-NGO-PTX have roughly the same diameter (around 280nm). TEM results confirm the information obtained from DLS and show that the synthesized nanoparticles are roughly irregular in shape with clear edges ( Figure 2C–E ). The PDI data show that these nanoparticles have good homogeneity. The zeta potential indicates the degree of electrostatic repulsion between adjacent nanoparticles, which is an important indicator of particle stability in solution. Studies have shown that particles with charges from ±10 to ±30 are generally considered to be stable. 9 , 11 Our data show that the synthesized RGD-TPGS-nGO-PTX has a suitable zeta potential (−23.42 mV), which indicates that it has good stability to a certain extent. The detailed characterization parameters are shown in Table 1 . Table 1 The Characteristic Parameters Include Particle Size, PDI and Zeta Potential In addition, we also performed a stability evaluation. In an aqueous medium, nGO and RGD-TPGS-nGO remained stable without any flocculation for 15 consecutive days. Although nGO showed visible precipitation and flocculation in saline on day 1 itself, RGD-TPGS-nGO showed excellent stability ( Figure 2F ). These findings indicated that the presence of RGD-TPGS may be suppressed the flocculation of nGO by masking the charged groups on the nGO surface. Additionally, TPGS acts as a surfactant and has dissolution-enhancing properties. 50 TPGS modification increased the viscosity of the nGO solution, leading to an inhibition of nanoparticle aggregation. 51 The mean drug loading capacity of RGD-TPGS-nGO-PTX was 48.78%. Elemental analysis revealed that the elemental content of N in nGO, TPGS-nGO, and RGD-TPGS-nGO was 0%, 0%, and 3.36%, respectively, indicating that RGD-TPGS-nGO had RGD-containing peptides. 52 Further, the elemental content of H in these nanoparticles was 2.30%, 6.63%, and 8.00%, respectively, showing a clear increasing trend ( Table 2 ). Table 2 Organic Element Analysis Assessment of RGD-TPGS-nGO Toxicity Zebrafish embryos are ideal models for testing drug toxicity in vivo because their optical transparency enables the monitoring of morphological changes ( Figure 3A ). 53 , 54 After incubation with 250 μg/mL of nGO, TPGS, and RGD-TPGS-nGO, zebrafish embryos were examined at 96 hours post-fertilization (hpf). The treated zebrafish embryos showed no significant differences in survival rate ( Figure 3B ), hatching rate ( Figure 3C ), heart rate ( Figure 3D ), and body length ( Figure 3E ) when compared with the control embryos. These results revealed that RGD-TPGS-nGO administration had no significant toxic effects on zebrafish embryos. Figure 3 Assessment of RGD-TPGS-nGO toxicity in vivo. (A) Morphological characterization, (B) Survival rate, (C) hatching rate, (D) heart rate, and (E) body length of zebrafish at 96 hours post-fertilization (hpf). Data are presented as mean ± standard deviation. The error bars represent the standard deviation values of ten independent repeats. Assessment of the Anti-Tumor Effect of RGD-TPGS-nGO-PTX in vitro We performed a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay to assess the anti-tumor effect of RGD-TPGS-nGO-PTX in MDA-MB-231 cells. Treatment with GO and RGD-TPGS-nGO had no significant impact on cell survival ( Figure 4A and B ). However, PTX and RGD-TPGS-nGO-PTX effectively decreased tumor cell viability ( Figure 4C and D ). Moreover, live/dead cell staining revealed that while RGD-TPGS-nGO administration did not affect MDA-MB-231 cells, PTX and RGD-TPGS-nGO-PTX treatment caused a significant reduction in tumor cell survival ( Figure 4E ). Figure 4 Assessment of the in vitro anti-tumor effect of RGD-TPGS-nGO-PTX. The survival rate of MDA-MB-231 cells after nGO (A), RGD-TPGS-nGO (B), PTX (C), and RGD-TPGS-nGO-PTX (D) administration. (E) Live/dead cell staining of MDA-MB-231 cells after treatment with different agents. Live cells were stained with Calcein-AM and dead cells were stained with PI. Data are presented as mean ± standard deviation. The error bars represent the standard deviation values of six independent repeats. **p<0.01. MDR Reversal by RGD-TPGS-nGO via Reductions in Mitochondrial Oxygen Consumption Rates Mitochondria are the powerhouses of cells and are involved in several metabolic processes and conditions. 55 , 56 Mitochondrial respiratory function is associated with tumor occurrence, development, and MDR. 57 , 58 To further explore how RGD-TPGS-nGO treatment suppresses tumor cell survival and growth, we detected the mitochondrial oxygen consumption rate (OCR) in MCF-7/ADR cells (human breast carcinoma cells showing drug resistance) using an XF96 Extracellular Flux Analyzer ( Figure 5A ). Comparisons with the control, results showed that nGO treatment had no significant effect on mitochondrial basal respiration, ATP production, proton leak, and maximal respiration in MCF-7/ADR cells. However, different concentrations of TPGS-nGO and RGD-TPGS-nGO significantly inhibited these processes and impaired respiratory function in mitochondria ( Figure 5B–F ). Taken together, these findings indicated that RGD-TPGS-nGO treatment could reverse MDR in MCF-7/ADR cells by suppressing mitochondrial respiratory function. Figure 5 Effect of RGD-TPGS-nGO on OCR in MCF-7/ADR cells. (A) Schematic of OCR analysis. (B) Effect of 25 μg/mL concentrations of different agents on OCR in MCF-7/ADR cells. Effect of various concentrations of different agents on basal respiration (C), ATP production (D), proton leak (E), and maximal respiration (F) in mitochondria from MCF-7/ADR cells. Data are presented as mean ± standard deviation. The error bars represent the standard deviation values of five independent repeats. **p<0.01. Assessment of the Anti-Tumor Effect of RGD-TPGS-nGO-PTX in vivo Animals in each group showed a significant increase in body weight over time, and these values were similar across all groups ( Figure 6A ). Furthermore, comparisons with the PTX and TPGS-nGO-PTX groups revealed that RGD-TPGS-nGO-PTX treatment attenuated the increase in tumor volume in mice ( Figure 6B and C ). Importantly, the RGD-TPGS-nGO-PTX group showed significantly higher PTX content in tumor tissues than the PTX and TPGS-nGO-PTX groups ( Figure 6D ). These results suggested that RGD-modified nGO had significant tumor-targeting capabilities. Moreover, these findings strongly indicated that TPGS-modified nGO might increase the in vivo circulation time of PTX and reverse MDR in tumor cells. Finally, the increased deposition of PTX in tumors by RGD-TPGS-nGO could also improve the treatment response. Figure 6 Assessment of the in vivo anti-tumor effect of RGD-TPGS-nGO-PTX. (A) Effect of RGD-TPGS-nGO-PTX on body weight in mouse models of breast cancer. (B) Effect of RGD-TPGS-nGO-PTX on tumor volume. Data are presented as mean ± standard deviation. Data are presented as mean ± standard deviation. The error bars represent the standard deviation values of five independent repeats. *p<0.05. (C) Representative images of tumor tissues from different groups of mice. (D) PTX concentrations in tumor tissues in the mice. Data are presented as mean ± standard deviation. The error bars represent the standard deviation values of three independent repeats. *p<0.05. Conclusions In this work, we established a multifunctional GO tumor-targeting drug delivery system using nGO modified with TPGS and RGD and loaded with PTX. RGD-TPGS-nGO administration showed no significant toxic effects in zebrafish embryos in vivo. Moreover, it could effectively suppress the survival of MDA-MB-231 cells and inhibit mitochondrial respiratory function in MCF-7/ADR cells in vitro. Further in vivo analyses in tumor-bearing mice showed that RGD-TPGS-nGO-PTX treatment significantly inhibits increases in tumor volume and enhances PTX concentrations in tumor tissue. These findings suggest that the RGD-TPGS-nGO nano delivery platform potential for enhancing PTX delivery and treatment efficacy in cases of BC. Data Sharing Statement The data that support the findings of this study are available from the corresponding author (Tongkai Chen) upon reasonable request. Acknowledgments This work was supported by the Key laboratory project of colleges and universities in Guangdong province (2019KSYS005), the Guangdong province science and technology plan international cooperation project (2020A0505100052), the Guangdong Basic and Applied Basic Research Foundation (2019B1515120043), the Research Fund of University of Macau (File no. MYRG2019-00121-ICMS and MYRG2018-00207-ICMS), the Science and Technology Development Fund, Macau SAR (File no. 0098/2020/A), the Key Sci-Tech Research Project of Guangzhou Municipality (202002020033), the Key Project of Basic Research of Shenzhen (JCYJ20200109113603854) and the Guangdong Provincial Natural Science Foundation of China (2018A030310623). Disclosure The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article. References

Seahorse Bioscience Frequently Asked Questions (FAQ)

  • When was Seahorse Bioscience founded?

    Seahorse Bioscience was founded in 2000.

  • Where is Seahorse Bioscience's headquarters?

    Seahorse Bioscience's headquarters is located at 16 Esquire Road, North Billerica.

  • What is Seahorse Bioscience's latest funding round?

    Seahorse Bioscience's latest funding round is Acquired.

  • How much did Seahorse Bioscience raise?

    Seahorse Bioscience raised a total of $28.84M.

  • Who are the investors of Seahorse Bioscience?

    Investors of Seahorse Bioscience include Agilent Technologies, Commonwealth Capital Ventures, EQT Life Sciences, Flagship Pioneering, New Science Ventures and 8 more.

  • Who are Seahorse Bioscience's competitors?

    Competitors of Seahorse Bioscience include Biocytogen, Biolog, PPD, LeadScope, Sertanty and 12 more.

Compare Seahorse Bioscience to Competitors

E
Ellipsis Biotherapeutics Corporation

Ellipsis is a biotechnology company that aims to provide single nucleotide polymorphism (SNP) genotyping to clients in the private, public and government sectors.

M
MI Research

MI Research, Inc. specializes in Biotech instrumentation with excellent visualization capabilities in the area of protein crystal growth and blood viscosity measurements. MI aims to offer fluorescence base protein crystallization prescreening service and biotech instruments like blood viscometers. MI's expertise is in optics and biochemistry.

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

W
Wilmington PharmaTech

Wilmington PharmaTech is a fully integrated CRO/CMO service company specializing in chemical process research, analytical method development and validation, trace chemical analysis, solid state polymorphic screening, and discovery studies for pharmaceutical and biotechnology industries.

M
Metagenomix

Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds.

W
Welgen

Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.